JAK 2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
暂无分享,去创建一个
Robert M. Vogel | M. Ladanyi | E. Stanchina | W. Pao | L. Norton | K. Manova-Todorova | G. Altan-Bonnet | D. Solit | M. Arcila | R. Levine | J. Bromberg | D. Lyden | S. Gao | D. Huszar | Haiying Zhang | L. Daly | M. Zinda | Q. Chang | E. Bournazou | L. Morris | T. Chan | Ninghui Mao | M. Brewer | S. Liu | Erez Schori
[1] P. Neven,et al. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. , 2015, Cancer treatment reviews.
[2] R. Coffey,et al. Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. , 2014, Annual review of physiology.
[3] Y. Yoshioka,et al. Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis. , 2013, Die Pharmazie.
[4] M. Lazzara,et al. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells , 2013, Journal of Cell Science.
[5] W. Pao,et al. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer , 2013, Proceedings of the National Academy of Sciences.
[6] R. Norton,et al. Suppressor of Cytokine Signaling (SOCS) 5 Utilises Distinct Domains for Regulation of JAK1 and Interaction with the Adaptor Protein Shc-1 , 2013, PloS one.
[7] W. Curran,et al. Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer , 2013, Molecular Cancer Therapeutics.
[8] D. Hilton,et al. Suppression of cytokine signaling: the SOCS perspective. , 2013, Cytokine & growth factor reviews.
[9] William Pao,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.
[10] Isabelle S. Lucet,et al. SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition , 2013, Nature Structural &Molecular Biology.
[11] P. Dobrzanski,et al. The many faces of Janus kinase. , 2012, Biochemical pharmacology.
[12] B. Nixon,et al. Suppressor of cytokine signaling 4 (SOCS4): Moderator of ovarian primordial follicle activation , 2012, Journal of cellular physiology.
[13] Mari Mino-Kenudson,et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.
[14] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[15] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[16] N. Normanno,et al. EGFR-targeted therapy. , 2011, Experimental cell research.
[17] R. Figlin,et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.
[18] Ying Zheng,et al. Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma , 2011, Molecular Cancer Therapeutics.
[19] E. Dolgin. Companies hope for kinase inhibitor JAKpot , 2011, Nature Reviews Drug Discovery.
[20] M. Ladanyi,et al. New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer , 2011, Clinical Cancer Research.
[21] D. Levy,et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.
[22] T. Lien,et al. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. , 2011, Biochemical pharmacology.
[23] Yosef Yarden,et al. Feedback regulation of EGFR signalling: decision making by early and delayed loops , 2011, Nature Reviews Molecular Cell Biology.
[24] M. Ladanyi,et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.
[25] Keara M. Lane,et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. , 2010, Cancer research.
[26] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[27] J. Khan,et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma , 2009, Cancer biology & therapy.
[28] Hua Yu,et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.
[29] G. Watanabe,et al. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2009, Clinical Cancer Research.
[30] R. Greil,et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Mithat Gonen,et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. , 2008, Cancer research.
[32] J. Turkson,et al. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. , 2008, Experimental cell research.
[33] W. Gerald,et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.
[34] Stefan Knapp,et al. Structure of the SOCS4-ElonginB/C Complex Reveals a Distinct SOCS Box Interface and the Molecular Basis for SOCS-Dependent EGFR Degradation , 2007, Structure.
[35] S. Thorgeirsson,et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. , 2007, The Journal of clinical investigation.
[36] W. Pao,et al. Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors , 2007, PloS one.
[37] F. Yakes,et al. Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647 , 2007, Clinical Cancer Research.
[38] G J Griffiths,et al. Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. , 2006, Systems biology.
[39] M. Ladanyi,et al. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[40] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[41] I. Amit,et al. Suppressors of Cytokine Signaling 4 and 5 Regulate Epidermal Growth Factor Receptor Signaling* , 2005, Journal of Biological Chemistry.
[42] W. Alexander,et al. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] P. Heinrich,et al. Janus Kinase (Jak) Subcellular Localization Revisited , 2004, Journal of Biological Chemistry.
[44] S. Papson,et al. “Model” , 1981 .
[45] 原田 大二郎. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation , 2013 .
[46] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[47] A. Sorkin,et al. Endocytosis and intracellular trafficking of ErbBs. , 2008, Experimental cell research.